NCT03326869终止不适用
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Implanted in Corneal Pockets With a Delayed or Non-Delayed Approach
Eye Center of North Florida1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2017年10月18日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Uncorrected Visual Acuity
研究概览
简要总结
The objective of this study is to evaluate the Raindrop® Near Vision Inlay for the improvement of near vision in presbyopes implanted in corneal pockets with a delayed or a non-delayed approach.
详细描述
Patients must be presbyopic with a reading add from +1.5 to +2.5 D, and both emmetropes (MRSE from -0.5 to +0.5 D) as well as ametropes (requiring concurrent LASIK) are included in the investigation. In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day. In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
No Masking.
入排标准
- 年龄范围
- 41 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.1 Inclusion Criteria:
- •1.1.1 Patients require a near reading add from +1.5 to +2.5 D in the non-dominant eye.
- •1.1.2 Patients have a photopic pupil size of at least 3.0 mm in the non-dominant eye.
- •1.1.3 Patients have a central corneal thickness ≥ 500 microns in the non-dominant eye.
- •1.1.4 Patients have corrected distance and near visual acuity of 20/25 or better in each eye.
- •1.1.5 Patients have uncorrected near acuity of 20/40 or worse in the non-dominant eye.
- •1.1.6 Patients are willing and able to understand and sign a written Informed Consent Form prior to any study-specific procedures.
- •1.1.7 Patients are willing and able to return for scheduled follow-up examinations for 24 months after corneal inlay implantation.
排除标准
- •1.1.1 Patients with clinically significant dry eye (i.e., significant diffuse punctate staining with fluorescein and a tear breakup time less than 8 s) in either eye.
- •1.1.2 Patients with a planned corneal residual bed thickness that is less than 300 microns (corneal thickness - (intended ablation depth + intended flap thickness)).
- •1.1.3 Patients with macular pathology based on dilated fundus exam and/or optical coherence tomography (OCT) image.
- •1.1.4 Patients who would be co-managed by an ophthalmologist or optometrist who is not approved as a ReVision Optics investigator.
- •1.1.5 Patients with ocular pathology or disease (including pupil pathology such as fixated pupils) that might confound the outcome or increase the risk of adverse event.
- •1.1.6 Patients taking systemic or topical medications that might confound the outcome or increase the risk of adverse event. Patients taking isotretinoin or amiodarone hydrochloride and any other medication that affects the tear film or accommodation, including but not limited to, mydriatic, cycloplegic and mitotic agents, tricyclic, phenothiazines, benzodiazepines, and first generation antihistamines.
- •1.1.7 Patients with known sensitivity to any planned study medications. 1.1.8 Patients with residual, recurrent, active or uncontrolled eyelid disease. 1.1.9 Patients with significant corneal asymmetry or irregular topography. 1.1.10 Patients with clinically significant anterior segment pathology. 1.1.11 Patients with any corneal abnormality, including but not limited to, slit lamp findings for corneal staining Grade 3 or higher, recurrent corneal erosion or severe basement membrane disease, and pterygium extending onto the cornea.
- •1.1.12 Patients with ophthalmoscopic/topographic signs of keratoconus or those who are keratoconus suspect.
- •1.1.13 Patients with history of Herpes zoster or Herpes simplex keratitis. 1.1.14 Patients with any progressive retinal disease or patients with a history or evidence of retinal vascular occlusion and/or hypercoagulability, because of the risks associated with high pressures during suction application.
- •1.1.15 Patients with known history of steroid-responsive intraocular pressure increases, glaucoma, preoperative IOP > 21 mm Hg, or are otherwise suspected of having glaucoma.
- •1.1.16 Patients with amblyopia or strabismus or those who are at risk for developing strabismus postoperatively as determined by corneal light reflex and cover-uncover testing.
- •1.1.17 Patients with diabetic retinopathy, collagen, vascular, diagnosed autoimmune disease (e.g., lupus, rheumatoid arthritis, fibromylagia), immunodeficiency (e.g., HIV), connective tissue disease, or clinically significant atopic syndrome such as allergies or asthma.
- •1.1.18 Patients on chronic systemic corticosteroid or other immunosuppressive therapy that may affect wound healing.
- •1.1.19 Patients with any type of active cancer (ophthalmic or non-ophthalmic). 1.1.20 Patients with uncontrolled infections of any kind. 1.1.21 Patients who are pregnant, lactating, of child-bearing potential and not practicing a medically approved method of birth control, or planning to become pregnant during the course of the trial, and patients with other conditions associated with fluctuation of hormones that could lead to refractive changes.
- •1.1.22 Patients who actively participate in contact sports (i.e., boxing, martial arts) where impacts to the face and eye are a normal occurrence.
- •1.1.23 Patients participating in any other ophthalmic or non-ophthalmic drug/device clinical trials during the time of this clinical investigation.
研究组 & 干预措施
Delayed
Experimental
Intervention: Raindrop Near Vision Inlay
In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day.
干预措施: Raindrop Near Vision Inlay (Device)
Non-Delayed
Active Comparator
Intervention: Raindrop Near Vision Inlay
In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day.
干预措施: Raindrop Near Vision Inlay (Device)
结局指标
主要结局
Uncorrected Visual Acuity
时间窗: 24 Months
After the inlay procedure, patients will attain functional near acuity in the inlay eye and functional distance vision binocularly.
次要结局
- Incidence of Corneal Reaction(24 Months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
A Prospective Study to Evaluate the Raindrop Near Vision Inlay With Mitomycin CPresbyopiaNCT03242317Fichte, Endl & Elmer Eyecare40
Unknown
4 期
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before ImplantationPresbyopiaNCT03126877Whitten Laser Eye40
Unknown
4 期
A Study to Evaluate the Raindrop Near Vision Inlay Under Flap or Within PocketPresbyopiaNCT03376412Whitten Laser Eye60
终止
4 期
A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.PresbyopiaNCT03101501Key-Whitman Eye Center9
Unknown
3 期
A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near and Intermediate Vision in Pseudophakic Presbyopic SubjectsPresbyopiaPseudophakiaNCT02668523ReVision Optics, Inc.400